Dehydroepiandrosterone (DHEA) ELISA
- Regulatory Status
- RUO
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 1 x 1 h; 1 x 30 min
- Standard range
- 0.37 - 30 ng/mL
- Specimen / Volumes
- 20 µL Serum
- Substrate / isotope
- TMB 450 nm
Dehydroepiandrosterone (DHEA) ELISA
Enzyme immunoassay for the quantitative determination of Dehydroepiandrosterone (DHEA) in human serum.
Dehydroepiandrosterone (DHEA; androstenolone; 3b-hydroxy-5-androsten-17-one) is a C19 steroid produced in the adrenal cortex and, to a lesser extent, gonads. DHEA serves as a precursor in testosterone and estrogen synthesis. Due to the presence of a 17-oxo (rather than hydroxyl) group, DHEA has relatively weak androgenic activity, which has been estimated at ~10 % that of testosterone. However in neonates, peripubertal children and in adult women, circulating DHEA levels may be several-fold higher than testosterone concentrations, and rapid peripheral tissue conversion to more potent androgens (androstenedione and testosterone) and estrogens may occur. Moreover, DHEA has relatively low affinity for sex-hormone binding globulin. These factors may enhance the physiologic biopotency of DHEA.
The physiologic role of DHEA has not been conclusively defined. A variety of in vitro effects, including antiproliferative effects in different cell lines and effects on enzyme-mediated cell metabolism, have been reported. In vivo studies suggest that DHEA may affect cholesterol and lipid metabolism, insulin sensitivity and secretion and immune function.
For concrete data please consult the Instruction for Use in the download box on the top right side.
(1) Kroboth, P. D., Salek, F. S., Pittenger, A. L., Fabian, T. J., & Frye, R. F. DHEA and DHEA‐S: A Review. J. Clin. Pharmacol. 1999, 39
(4),), 327-348.
(2) Flier, J. S., & Foster, D. W. Eating Disorders: Obesity, Anorexia Nervosa, and Bulimia Nervosa. Williams Textbook of
Endocrinology. Williams Textb. Endocrinol. Eat. Disord. obesity, Anorex. Nerv. Bulim. Nerv. Saunders, Philadelphia, PA. 1998.
(3) Baulieu, E. E.; Robel, P. Dehydroepiandrosterone (DHEA) and Dehydroepiandrosterone Sulfate (DHEAS) as Neuroactive
Neurosteroids. Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (8), 4089–4091. https://doi.org/10.1073/pnas.95.8.4089.
(4) Heaney, J. L. J.; Phillips, A. C.; Carroll, D. Ageing, Physical Function, and the Diurnal Rhythms of Cortisol and
Dehydroepiandrosterone. Psychoneuroendocrinology 2012, 37 (3), 341–349.
https://doi.org/10.1016/j.psyneuen.2011.07.001.
(5) Al-Turk, W., & Al-Dujaili, E. A. Effect of Age, Gender and Exercise on Salivary Dehydroepiandrosterone Circadian Rhythm
Profile in Human Volunteers. Steroids, 2016, 106, 19–25.
(6) Guilliams, T. The Role of Stress and the HPA Axis in Chronic Disease Management. Point Inst. 2018, 80.
(7) Guilliams, T. G.; Edwards, L. Chronic Stress and the HPA Axis: Clinical Assessment and Therapeutic Considerations. Stand.
2010, 9 (2), 1–12.
(8) Shoback, D., & Gardner, D. G. (Eds. ). Greenspan’s Basic & Clinical Endocrinology. McGraw-Hill Educ. 2018.
(9) El-Gharib, M.; El-Din Hazaa, S. Salivary versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia. J. Basic
Clin. Reprod. Sci. 2014, 3 (1), 54. https://doi.org/10.4103/2278-960x.129283.
(10) Berg, G.; Wagner-Doebler, I.; Maree Burke, C.; Lindheim, L.; Bashir, M.; Münzker, J.; Trummer, C.; Zachhuber, V.; Pieber, T. R.;
Gorkiewicz, G.; Obermayer-Pietsch, B. The Salivary Microbiome in Polycystic Ovary Syndrome (PCOS) and Its Association with
Disease-Related Parameters: A Pilot Study. Front. Microbiol. | www.frontiersin.org 2016, 1, 1270.
https://doi.org/10.3389/fmicb.2016.01270.
(11) Tock, L.; Carneiro, G.; Pereira, A. Z.; Tufik, S.; Zanella, M. T. Adrenocortical Production Is Associated with Higher Levels of
Luteinizing Hormone in Nonobese Women with Polycystic Ovary Syndrome. Int. J. Endocrinol. 2014, 2014.
https://doi.org/10.1155/2014/620605.
(12) King, J. A.; Wisniewski, A. B.; Bankowski, B. J.; Carson, K. A.; Zacur, H. A.; Migeon, C. J. Long-Term Corticosteroid Replacement
and Bone Mineral Density in Adult Women with Classical Congenital Adrenal Hyperplasia. J. Clin. Endocrinol. Metab. 2006, 91
(3), 865–869. https://doi.org/10.1210/jc.2005-0745.
(13) Migeon CJ, W. A. Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency. Endocrinol Metab Clin North Am
2001, 30:, 193–206.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.